MarketsandMarkets Biomarker and Companion Diagnostics Conference-East Coast Edition

WHAT TO EXPECT

Commercialization of CDx
Proteomics and Genomics based Biomarkers
Biomarker Drug Discovery and Assay Development
Multiplex Companion Diagnostics and Regulatory Guidelines
Design of clinical trials in CDx
Digital Biomarkers, Predictive Biomarkers, Precision Medicine and Big Data
Clinical Applications of Biomarkers in Immuno-Oncology, Neurology and Inflammatory Diseases

Researchers, scientists, clinicians, academicians and professionals from Pharmaceutical companies, Bio-pharma companies & Universities and Research institutes working in:

Biomarker discovery/development
Translational research
Clinical Biomarker
Biomarkers in IO and Neurological disorders
Imaging Biomarkers
Pathology
Companion Diagnostics
Biomarker Imaging
Proteomics Biomarkers
Experimental Medicine
Data Science
Biomarkers in Clinical Discovery
Immuno-oncology/Neuroscience Drug Discovery
Diagnostic Biomarkers development
Personalized Medicine
Immunology Biomarkers

CONFERENCE AGENDA

Registration	08:15 - 08:50
Welcome note from MarketsandMarkets	08:50 - 09:05
Opening Remarks from the Chairman	09:05 - 09:10
Keynote Presentation - To be confirmed FDA/NIH	09:10 - 09:40
Clinical Biomarker Validation and Assay Development
Personalized approach for identifying and tracking Molecular residual disease in Solid tumor Xinru Mao, Vice President, Biomarker & CDx Service, Burning Rock Dx	09:40 - 10:10
Solution Provider Presentation-Reserved for Gold Sponsor	10:10 - 10:25
Morning Refreshments and Poster Presentation \| One-to-One Networking Meetings	10:25 - 11:10
Functional biomarker assay development for cancer treatment	11:10 - 11:40
Solution Provider Presentation-Reserved for Silver Sponsor	11:40 - 12:10
Studying the clinical change of paradigm in liquid biopsies	12:10 - 12:40
Use of biomarkers in clinics-success and challenges of getting a good biomarker	12:40 - 13:10
Lunch and Poster Presentation \| One-to-One Networking Meetings	13:10 - 14:10
Role of Biomarkers in Personalized Medicine
Precision Oncology Centric Development of Antibody Drug Conjugates Rakesh Dixit, CEO, Bionavigen	14:10 - 14:40
Identification of New Targets and Precision Medicines through Single Molecule Tracking in Live Cells Roy Baynes, Executive Vice President, Chief Medical Officer, Eikon Therapeutics	14:40 - 14:55
Why is monitoring predictive biomarker data so difficult for big pharma?	14:55 - 15:25
Assessing clinical and pharmacodynamic data in a phase I/Ib study with hetIL15 (NIZ985) and in combination with anti-PD1 (PDR001) in patients with solid tumors Nadia Hassounah, Principal Scientist, Novartis	15:25 - 15:55
Afternoon Refreshments and Poster Presentation \| One-to-One Networking Meetings	15:55 - 16:40
Patient Identification and Stratification applying predictive models	16:40 - 17:10
Use of Real World Evidence in discovery of digital biomarkers	17:10 - 17:25
Solution Provider Presentation	17:25 - 17:55
Closing Remarks from the Chairman	17:55 - 17:55
End of Day 1 followed by Drinks Reception and Networking	17:55 - 17:55

Registration	08:15 - 09:00
Welcome note from MarketsandMarkets	09:00 - 09:05
Opening Remarks from the Chairman	09:05 - 09:10
Keynote Presentation Kristina McGuire, Executive Director and Head of CDx & Lab Operations, Precision Medicine, Regeneron Pharmaceuticals	09:10 - 09:40
From Biomarkers to CDx: Strategies to accelerate CDx development and Commercialization
Strategies to optimize CDx in cancer	09:40 - 10:10
Solution Provider Presentation-Reserved for Gold Sponsor	10:10 - 10:25
Morning Refreshments and Poster Presentation \| One-to-One Networking Meetings	10:25 - 11:10
Building up a successful CDx partnership with Pharma	11:10 - 11:40
Solution Provider Presentation-Reserved for Silver Sponsor	11:40 - 11:55
CDx Launch Success: From Early Biomarker Development to Commercialization	11:55 - 12:10
Clinical Applications of Biomarkers in Cancer and Neurology
Solution Provider Presentation	12:10 - 12:40
A multi tumor survey of Nectin-4 expression to guide BT8009 indication selection Carly Campbell, Principal Scientist, Translational Science & Diagnostics, Bicycle Therapeutics	12:40 - 13:10
Lunch and Poster Presentation \| One-to-One Networking Meetings	13:10 - 14:10
Solution Provider Presentation	14:10 - 14:25
Leveraging IO markers for companion diagnostics development	14:25 - 14:55
Solution Provider Presentation	14:55 - 15:25
Innovative Safety Biomarker Applications to Drug Development	15:25 - 15:25
End of Conference	15:25 - 15:25